CSF2 and melanoma: Specifically, they reported a pilot Phase II clinical trial including 28 clinical-stage I-II melanoma patients receiving, before the SLN biopsy, intradermal injections of saline or DC-targeting agents (low-dose Cytosine-phosphate-Guanine (CpG-B), alone or combined with GM-CSF) around the melanoma excision site [59,60].